CA3124316C - Cancer treatment using docetaxel by controlling peak plasma levels - Google Patents

Cancer treatment using docetaxel by controlling peak plasma levels Download PDF

Info

Publication number
CA3124316C
CA3124316C CA3124316A CA3124316A CA3124316C CA 3124316 C CA3124316 C CA 3124316C CA 3124316 A CA3124316 A CA 3124316A CA 3124316 A CA3124316 A CA 3124316A CA 3124316 C CA3124316 C CA 3124316C
Authority
CA
Canada
Prior art keywords
docetaxel
administration
cancer
use according
plasma levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3124316A
Other languages
English (en)
French (fr)
Other versions
CA3124316A1 (en
Inventor
Jacob Hendrik Beijnen
Johannes Henricus Matthias Schellens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Modra Pharmaceuticals BV
Original Assignee
Modra Pharmaceuticals BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modra Pharmaceuticals BV filed Critical Modra Pharmaceuticals BV
Publication of CA3124316A1 publication Critical patent/CA3124316A1/en
Application granted granted Critical
Publication of CA3124316C publication Critical patent/CA3124316C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3124316A 2018-12-21 2019-12-18 Cancer treatment using docetaxel by controlling peak plasma levels Active CA3124316C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18215472 2018-12-21
EP18215472.4 2018-12-21
PCT/EP2019/086124 WO2020127606A1 (en) 2018-12-21 2019-12-18 Cancer treatment using docetaxel by controlling peak plasma levels

Publications (2)

Publication Number Publication Date
CA3124316A1 CA3124316A1 (en) 2020-06-25
CA3124316C true CA3124316C (en) 2023-07-04

Family

ID=64901394

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3124316A Active CA3124316C (en) 2018-12-21 2019-12-18 Cancer treatment using docetaxel by controlling peak plasma levels

Country Status (14)

Country Link
US (3) US20220079910A1 (https=)
EP (2) EP3897610B1 (https=)
JP (3) JP2022515249A (https=)
KR (1) KR20220002860A (https=)
CN (1) CN113543781A (https=)
AU (2) AU2019410060A1 (https=)
BR (1) BR112021012255A2 (https=)
CA (1) CA3124316C (https=)
CL (1) CL2021001638A1 (https=)
ES (1) ES3026709T3 (https=)
IL (1) IL284213A (https=)
MX (2) MX2021007478A (https=)
PE (1) PE20220250A1 (https=)
WO (1) WO2020127606A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020127607A1 (en) * 2018-12-21 2020-06-25 Modra Pharmaceuticals B.V. Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor
PE20220250A1 (es) * 2018-12-21 2022-02-16 Modra Pharmaceuticals B V Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma
GB202201935D0 (en) 2022-02-14 2022-03-30 Modra Pharmaceuticals B V Methods and compositions for treating cancer in taxane-resistant patients

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
US9089544B2 (en) * 2007-08-24 2015-07-28 Slotervaart Participaties Bv Composition
GB0716591D0 (en) * 2007-08-24 2007-10-03 Vereniging Het Nl Kanker I Composition
MX2010002179A (es) * 2007-08-24 2010-04-27 Stichting Het Nl Kanker I Composicion para el tratamiento de enfermedades neoplasicas.
JP2012500788A (ja) 2008-08-22 2012-01-12 スティヒティング ヘット ネーデルランド カンケル インスティテュート 組成物
WO2020127607A1 (en) * 2018-12-21 2020-06-25 Modra Pharmaceuticals B.V. Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor
PE20220250A1 (es) * 2018-12-21 2022-02-16 Modra Pharmaceuticals B V Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma

Also Published As

Publication number Publication date
EP4670718A2 (en) 2025-12-31
CA3124316A1 (en) 2020-06-25
JP2022515249A (ja) 2022-02-17
BR112021012255A2 (pt) 2021-09-28
CL2021001638A1 (es) 2022-04-22
IL284213A (en) 2021-08-31
JP2023102787A (ja) 2023-07-25
AU2019410060A1 (en) 2021-08-05
MX2025008270A (es) 2025-08-01
EP4670718A3 (en) 2026-03-04
US20220323399A1 (en) 2022-10-13
US20220079910A1 (en) 2022-03-17
EP3897610C0 (en) 2025-04-16
AU2023204682A1 (en) 2023-08-10
EP3897610B1 (en) 2025-04-16
KR20220002860A (ko) 2022-01-07
EP3897610A1 (en) 2021-10-27
CN113543781A (zh) 2021-10-22
JP2025094189A (ja) 2025-06-24
ES3026709T3 (en) 2025-06-12
PE20220250A1 (es) 2022-02-16
US20250312305A1 (en) 2025-10-09
MX2021007478A (es) 2021-10-13
WO2020127606A1 (en) 2020-06-25
US11571408B2 (en) 2023-02-07

Similar Documents

Publication Publication Date Title
US20250312305A1 (en) Cancer Treatment Using Docetaxel by Controlling Peak Plasma Levels
AU2023204693A1 (en) Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor
US20130330326A1 (en) Methods of treating cancer
CN112533610B (zh) 用于治疗腺样囊性癌的包含双氟烷基-1,4-苯并二氮杂䓬酮化合物的组合物
US20260027117A1 (en) Methods of treating small cell lung cancer
US20220241294A1 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer
EP3302483B1 (en) Pharmaceutical compositions and use thereof
US20200345687A1 (en) Methods and compositions for treating chemotherapy-induced diarrhea
EP4385507A1 (en) Combination treatment for solid tumors using cabazitaxel and a cyp3a inhibitor
HK40111479A (en) Combination treatment for solid tumors using cabazitaxel and a cyp3a inhibitor
US20250302813A1 (en) Recombinant methioninase in the treatment of cancer
Mans et al. Phase I Study of Three-Times Daily Oral Etoposide in Patients with Refractory Solid Tumours.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210618

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 5TH ANNIV.) - SMALL

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241209

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - SMALL

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251125

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251125